Zum Inhalt springen
Home » HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

HepaRegenix, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and…

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration